Drug-induced lung diseases.
DOI:
https://doi.org/10.52692/1857-0011.2024.2-79.40Keywords:
lung diseases, toxicity, side effectsAbstract
Drug-induced lung injury (DILI) has been estimated to be caused by direct toxicity and immune-mediated toxicity. Direct toxicity can occur due to direct injury caused by the drug preparation or through the production of reactive metabolites, induction of oxidative stress and direct cytotoxicity on alveolar epithelial and endothelial cells with the onset of inflammation and pulmonary edema. Immune-mediated pulmonary toxicity may present as allergic, idiosyncratic reactions, immune cell infiltration and cytokine release. Drug-induced lung diseases can be categorized into acute (acute respiratory distress syndrome, hypersensitivity reactions) and chronic (interstitial lung disease, pulmonary fibrosis, etc.). The genesis of drug-induced lung diseases may involve antineoplastic (47.69%), cardiovascular (11,18%), antirheumatic (9.98%), antimicrobial (5.86%), hormonal (5.66%), immunomodulatory (3.83%), hematologic (3.51%), gastrointestinal (2.53%), analgesic and non-steroidal anti-inflammatory (2.38%), psychotropic (2.18%), drugs with influence on the central nervous system (2.01%), urinary (1.05%) and respiratory (0.77%).
References
Annareddy S., Ghewade B., Jadhav U., Wagh P. Navigating Drug-Induced Lung Disease (DILD): A Comprehensive Reviewon Management and Prevention Strategies. Cureus. 2024 Sep 22;16(9):e69954
Bridi G.D.P., Fonseca E.K.U.N, Kairalla R.A.et al. Drug-induced lung disease: a narrative review. J Bras Pneumol. 2024;50(4):e20240110.
Conte P., Ascierto P.A., Patelli G.et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022 Apr;7(2):100404.
Gidaris D., Priftis N., Anthracopoulos M. B. Pulmonary Complications of Drug Therapy. Respiratory Medicine, 2017 241–262.
Gonçalves D., Moura R., Ferraz C.et al. Carbamazepine-induced interstitial pneumonitis associated with pan-hypogammaglobulinemia. Respir. Med. Case Rep., 2012; 5: 6-8.
Jiang T., Su H., Xu J.et al. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021. Ther Adv Drug Saf. 2024 Jan 27;15:20420986231224227.
Jo T., Michihata N., Yamana H.et al. Risk of drug- induced interstitial lung disease in hospitalised patients: a nested case-control study. Thorax. 2021 Dec;76(12):1193-1199.
Liapikou A., Cilloniz C., Torres A. Drugs that increase the risk of community-acquired pneumonia: a narrative review. Expert Opin Drug Saf. 2018 Oct;17(10):991-1003.
Matsumoto M., Ito I., Kadowaki S. Drug-induced interstitial lung disease due to over-the-counter cold medicine taken daily for 25 years: a case report. J Med Case Rep. 2023 Feb 27;17(1):83.
Özkan M., Dweik R.A., Ahmad M. Drug-induced lung disease. Cleveland Clinic Journal of Medicine, 2001; 68(9): 636-642.
Raghunathan N., Balasubramanian A., Ramalingam R. Drug Induced Pulmonary Disease-A Mini Review. Res. J. Pharm. and Tech., 2019; 12(9): 4583-4588.
Sato S., Oba T., Ohta H.et al. Levetiracetam-induced interstitial lung disease in a patient with advanced lung cancer. Respir Med Case Rep. 2020 Sep 28;31:101241.
Taipale H., Lampela P., Koponen M. et al. Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer’s Disease-Matched Cohort Study. J Alzheimers Dis. 2019;68(1):127-136.
Ufuk F., Bayraktaroğlu S., Rüksan Ütebey A. Drug- induced lung disease: a brief update for radiologists. Diagn Interv Radiol. 2023 Jan 31;29(1):80-90.
Анаев Э.Х. Лекарственно-индуцированное интерстициальное заболевание легких: подходы к диагностике и лечению. Терапевтический архив. 2020; 92 (3): 84–91. doi: 10.26442/00403660.2020.03.000399.
Остроумова О.Д., Листратов А.И., Кочетков А.И., Сычёв Д.А. Лекарственные средства, приём которых ассоциирован с развитием лекарственно- индуцированных интерстициальных заболеваний лёгких. Качественная клиническая практика. 2021;(2):39-51. doi.org/10.37489/2588-0519-2021-2-39-51.
Орлова Н. В., Остроумова О. Д., Ших Е. В. и др. Лекарственно-индуцированные поражения легких противоопухолевыми препаратами: диагностика, особенности клинического течения, факторы риска, дифференциальный диагноз, лечение, профилактика. ч. 1. Туберкулёз и болезни лёгких. 2021. 99 (7):55-62. doi.org/10.21292/2075-1230- 2021-99-7-55-62.
Downloads
Published
License
Copyright (c) 2025 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
